Elizabeth S. Duke

MedicineNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors”.

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0459

N/A

2.2DataRank · unranked

84 citations

Diana Bradford, Michelle Marcovitz, Anup Amatya, Pallavi S. Mishra‐Kalyani, Emily Nguyen +17 more

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2072

N/A

1.7DataRank · unranked

42 citations

Liza Stapleford, Nicole Drezner, Anup Amatya, Pallavi S. Mishra‐Kalyani, Yuan Li Shen +22 more

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

Nature Medicine(2023)10.1038/s41591-023-02464-8

N/A

0.604DataRank · unranked

55 citations

Kelly Hotchkiss, Ian F. Parney, John de Groot, Solmaz Sahebjam, Nader Sanai +31 more

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

Journal of Clinical Oncology(2024)10.1200/jco.24.00546

N/A

0.584DataRank · unranked

15 citations

Diana Bradford, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Catherine C. Lerro, Donna R. Rivera +13 more

A brave new framework for glioma drug development

The Lancet Oncology(2024)10.1016/s1470-2045(24)00190-6

N/A

0.494DataRank · unranked

26 citations

Philipp Karschnia, Karisa C. Schreck, Marjolein Geurts, Timothy F. Cloughesy, Jason T. Huse +34 more

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0873

N/A

0DataRank · unranked

48 citations

Amy Barone, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Emasenyie Isikwei +14 more

Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3386

N/A

0DataRank · unranked

12 citations

Robert A. Avery, Michael J. Fisher, Roger J. Packer, Karin S. Walsh, Antoinette Y. N. Schouten‐van Meeteren +8 more